Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 4/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 17/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980078 | 0.89 | PIK3CA (0.59) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL7917870 | 0.87 | PIK3CA (0.51) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359212 | 0.86 | PIK3CA (0.62) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359843 | 0.86 | MTOR (0.55) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL11980081 | 0.86 | PIK3R1 (0.65) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL7904273 | 0.86 | MTOR (0.49) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359593 | 0.86 | MTOR (0.49) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359441 | 0.85 | MTOR (0.54) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL1359623 | 0.85 | PIK3CA (0.64) | MTORPIK3CAPIK3R1PIK3CDPIK3CB | |
| SCHEMBL7920905 | 0.85 | MTOR (0.64) | MTORPIK3CAPIK3CGMAPK14CSNK1G1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | claimed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | claimed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | claimed |
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | claimed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | MTOR 1/4885PIK3CA 2/4885PIK3R1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.